Sign in
CompletedNo phase

Microneedling-Assisted Delivery of Cetirizine Versus Latanoprost in Alopecia Areata

Key facts

Who runs it
Tanta University
Where
Egypt1 site in 1 countryChoose a country to see its sites
Trial code
Status
Completed
People taking part
80 people enrolled
Started
1 Oct 2022
Ended
1 Oct 2024
Type of study
Interventional, 4 groupsOne group gets an existing treatment, for comparison.
Treatments tested
  • Cetirizine (Zyrtec)
  • Latanoprost
  • Triamcinolone Acetonide
  • Microneedling only
Record updated
11 August 2026

Who can take part

Sex
Women and men
Healthy volunteers
Can take part

The registry criteria, word for word

Show all 13 criteriaShow less

Who can take part

  • Newly diagnosed cases of alopecia areata
  • Patients of any age
  • Both male and female patients
  • Recent-onset patchy alopecia areata of ≤6 months' duration
  • Presence of no more than two alopecia patches
  • Stationary course of the disease
  • Willingness to participate in the study
  • Provision of written informed consent or parental/guardian consent for minors

Who cannot take part

  • Previous treatment of the alopecia areata lesions
  • Active scalp infection
  • Presence of associated dermatological, systemic, or autoimmune comorbidities
  • Known allergy or hypersensitivity to any of the planned therapeutic agents
  • Extensive alopecia areata, including alopecia totalis or alopecia universalis

This trial has no sites in United States.

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

This study planned to measure the effectiveness and safety of microneedling aided administration of cetirizine 1% versus latanoprost 0.01% in alopecia areata.

The 4 groups in the trial

  • Group ATreatment being tested

    Patients treated with microneedling-aided administration of topical cetirizine 1% solution.

    Treatment: Cetirizine (Zyrtec)

  • Group BTreatment being tested

    Patients treated with microneedling-aided administration of topical latanoprost 0.01% solution.

    Treatment: Latanoprost

  • group CExisting treatment, for comparison

    Patients treated with microneedling-aided administration of topical triamcinolone acetonide (TrA) (10mg/ml) as a positive control group

    Treatment: Triamcinolone Acetonide

  • Group DExisting treatment, for comparison

    Patients treated with microneedling only as a negative control group

    Treatment: Microneedling only

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
Microneedling-Assisted Delivery of Cetirizine Versus Latanoprost in Alopecia Areata: A Pilot Randomized Controlled Study
Record updated
11 August 2026